Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06735924

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Led by University of Alabama at Birmingham · Updated on 2025-12-19

28

Participants Needed

1

Research Sites

244 weeks

Total Duration

On this page

Sponsors

U

University of Alabama at Birmingham

Lead Sponsor

N

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

CONDITIONS

Official Title

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years
  • History of MASLD with liver fat content greater than 5%
  • Normal kidney function
  • Stable medication for diabetes mellitus for at least 1 month if applicable
  • Willingness to follow fixed diets, stop dietary supplements, and attend study visits at UAB
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Inaccurate 24-hour urine collections
  • Liver fat content less than 5%
  • Liver cirrhosis
  • Other chronic liver diseases or viral hepatitis
  • History of alcoholism within 2 years prior to enrollment
  • Contraindication to Magnetic Resonance Imaging
  • Chronic kidney disease with estimated glomerular filtration rate below 60 ml/min/1.73m2
  • Type 1 diabetes mellitus or insulin treatment
  • Uncontrolled diabetes
  • Pregnancy, lactation, or intention to become pregnant
  • Uncontrolled hypertension
  • Use of weight loss medication, SGLT2 inhibitors, GLP-1 receptor agonists, osteoporosis medication, or chronic NSAIDs
  • History of gastric or intestinal surgery altering oxalate absorption
  • Chronic fat malabsorption
  • Use of immunosuppressive medications
  • Known immunocompromised status
  • Active malignancy or treatment within last 12 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294

Actively Recruiting

Loading map...

Research Team

K

Kyle D Wood, MD

CONTACT

S

Sonia Fargue, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here